게잡이 원숭이에 있어 rHuEPO(HM10760)의 단회 투여 후 혈액학 및 혈액생화학적 변화 = Changes in Hematological and Serum Biochemical Parameters After Single Dose of Recombinant Human Erythropoietin (HM10760) in Male Cynomolgus Monkeys

다국어 초록 (Multilingual Abstract)

Changes in hematology and serum biochemistry after treatment of recombinant human erythropoietin (rHuEPO, HM10760) were screened in 4 male cynomolgus monkeys (Macaca fascicularis). Four monkeys, composed of a treatment group of HM10760 and a positive control group of Aranesp<SUP>®</SUP>, were subcutaneously administered at same dose of 100 ㎍/㎏. Both groups did not show any change in body weights and food consumption for 4 weeks compared with those of pretreatment. Both groups did not show any change in total leukocyte count (WBC) and platelet count, while both groups showed increased platelet distribution width (PDW) percentage in HM10760 group during a period from day 5 to day 59 and in Aranesp<SUP>®</SUP> group during a period from day 9 to day 26. Both groups showed increases in red blood cells (RBC), hemoglobin (HGB), and hematocrit (HCT) approximately 10 days after treatment compared with those of pretreatment (day 0). The increased levels of RBC, HGB, and HCT were much higher in HM10760 than in Aranesp<SUP>®</SUP> by the increases of 3.2%~ 12.5% for RBC, 3.8%~17.1% for HCT, and 1.85%~11% for HGB. Both groups showed increases in red cells distribution width (RDW) and reticulocyte (RET) compared with those of pretreatment, showing the highest peak from day 9. The increased level of RET lasted up to day 14 in Aranesp<SUP>®</SUP> group, while it lasted up to day 23 in HM10760 group. The increased level of RDW lasted up to day 59, it was much higher in HM10760 by the increase of 10.1%~17.6% than in Aranesp<SUP>®</SUP> group. In serum biochemistry, both groups showed a decrease in chloride level compared with those of pretreatment. These findings indicated that HM10760 increased RBC, HGB, HCT, RDW, and RET compared with those of pretreatment, and the increased levels were much higher in HM10760 than in Aranesp<SUP>®</SUP>.

목차 (Table of Contents)

• ABSTRACT
• 서론
• 재료 및 방법
• 결과
• 고찰
• 감사의 말씀
• 참고문헌

참고문헌 (Reference)

1 "토끼에서 EPO(erythropoietin)의 4주간 정맥 반복투여 독성시험에 관한 연구" 13 : 139-147, 1997

2 "유전자재조합 의약품 연구동향" 30-38, 2004

3 "새로운 유전 공학적 방법에 의해 생산한 Erythropoietin의 rat에서의 4주 아급성 독성" 243-254, 1994

4 "비글견에서 인체 재조합 적혈구 조혈인자 rHu-EPO의 급성독성에 관한 연구" 6 : 317-327, 1998

5 "랫드에서 EPO(erythropoietin) 의 4주간 정맥 반복투여 독성시험" 13 : 131-138, 1997

6 "게잡이 원숭이에 있어 rHuEPO의 4주간 투여 후 혈액학 및 조직병리학적 변화" 21 : 227-234, 2005

7 "Use of recombinant human erythropoietin as an anti-anemic and performance enhancing drug" 1 : 11-31, 2000

8 "Thirteen-week intravenous toxicity study of EPOCH in rhesus monkeys" furu : 271-289, 1990

9 "The in vivo effects of recombinant human erythropoietin on cisdiamminodichloroplatinum-induced anemia in Golden Syrian hamsters" 149-152, 1991

10 "Response to exercise after blood loss and reinfusion" 175-180, 1972

11 "Recombinant erythropoietin in clinical practice." 79 : 367-376, 2003

12 "Recent advances in erythropoietin re- search" 293-311 : 1993

13 "Plateletcrit, mean platelet volume, platelet distribution width: its expected values and correlation with parallel red blood cell parameters" 10 : 175-178, 2004

14 "Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization" 71 : 524-527, 1988

15 "Isolation and characterization of genomic and cDNA clones of human erythropoietin" 806-810, 1985

16 "Guidelines for recombinant human erythropoietin therapy" 2-8, 1989

17 "Glycomics: a pathway to a class of new and improved therapeutics" 3 : 863-873, 2004

18 "Erythropoietin therapy: need for rationality and active surveillance" 88 : 601-605, 2003

19 "Erythropoietin enhances recovery from cisplatin-induced acute renal failure" 266 : 1994

20 "Effect of transportation on hematological and serum biochemical values in cynomolgus monkeys" 20 : 328-332, 2004

21 "Cloning and expression of the human erythropoietin gene" 7580-7584, 1985